{"id":"https://openalex.org/W2921487706","doi":"https://doi.org/10.1182/blood-2018-99-119129","title":"Pembrolizumab in Combination with Standard RCHOP Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma","display_name":"Pembrolizumab in Combination with Standard RCHOP Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma","publication_year":2018,"publication_date":"2018-11-29","ids":{"openalex":"https://openalex.org/W2921487706","doi":"https://doi.org/10.1182/blood-2018-99-119129","mag":"2921487706"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2018-99-119129","doi":"https://doi.org/10.1182/blood-2018-99-119129","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2018-99-119129","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5088459737","display_name":"Stephen Douglas Smith","orcid":"https://orcid.org/0000-0001-5354-7593","observed_orcids":["https://orcid.org/0000-0001-5354-7593"]},"institutions":[{"id":"https://openalex.org/I1332479046","display_name":"Seattle Cancer Care Alliance","ror":"https://ror.org/03jq88n71","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1332479046"]},{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephen D. Smith","raw_affiliation_strings":["Seattle Cancer Care Alliance, University of Washington, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Seattle Cancer Care Alliance, University of Washington, Seattle, WA","institution_ids":["https://openalex.org/I1332479046","https://openalex.org/I201448701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005281918","display_name":"Ryan C. Lynch","orcid":"https://orcid.org/0000-0001-6703-0894","observed_orcids":["https://orcid.org/0000-0001-6703-0894"]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]},{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ryan C. Lynch","raw_affiliation_strings":["University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA","institution_ids":["https://openalex.org/I201448701","https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037938194","display_name":"Brian G. Till","orcid":"https://orcid.org/0000-0002-4718-8288","observed_orcids":["https://orcid.org/0000-0002-4718-8288"]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Brian G. Till","raw_affiliation_strings":["Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA","institution_ids":["https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024384857","display_name":"Andrew J. Cowan","orcid":"https://orcid.org/0000-0002-1880-7094","observed_orcids":["https://orcid.org/0000-0002-1880-7094","https://orcid.org/0000-0003-2326-2727"]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrew J. Cowan","raw_affiliation_strings":["Fred Hutchinson Cancer Research Center, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fred Hutchinson Cancer Research Center, Seattle, WA","institution_ids":["https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027819567","display_name":"Qian Vicky Wu","orcid":"https://orcid.org/0000-0002-2292-4816","observed_orcids":["https://orcid.org/0000-0002-2292-4816"]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Qian V. Wu","raw_affiliation_strings":["Fred Hutchinson Cancer Research Center, Department of Clinical Biostatistics, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fred Hutchinson Cancer Research Center, Department of Clinical Biostatistics, Seattle, WA","institution_ids":["https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057524392","display_name":"Jenna M. Voutsinas","orcid":"https://orcid.org/0000-0002-7474-4892","observed_orcids":["https://orcid.org/0000-0002-7474-4892"]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Jenna M. Voutsinas","raw_affiliation_strings":["Fred Hutchinson Cancer Research Center, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fred Hutchinson Cancer Research Center, Seattle, WA","institution_ids":["https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051296565","display_name":"Mazyar S. Shadman","orcid":"https://orcid.org/0000-0002-3365-6562","observed_orcids":["https://orcid.org/0000-0002-3365-6562"]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mazyar Shadman","raw_affiliation_strings":["Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA","institution_ids":["https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055972784","display_name":"Katie Blue","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]},{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Katie Blue","raw_affiliation_strings":["University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA","institution_ids":["https://openalex.org/I201448701","https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059661907","display_name":"Andrei R. Shustov","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Andrei R. Shustov","raw_affiliation_strings":["University of Washington, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Washington, Seattle, WA","institution_ids":["https://openalex.org/I201448701"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022775720","display_name":"Sandra Kanan","orcid":"https://orcid.org/0000-0003-0841-3558","observed_orcids":["https://orcid.org/0000-0003-0841-3558"]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]},{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sandra Kanan","raw_affiliation_strings":["University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA","institution_ids":["https://openalex.org/I201448701","https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040951672","display_name":"Lauren Low","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]},{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Lauren Low","raw_affiliation_strings":["University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA","institution_ids":["https://openalex.org/I201448701","https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071844603","display_name":"Ryan Daniel Cassaday","orcid":"https://orcid.org/0000-0002-3424-2425","observed_orcids":["https://orcid.org/0000-0002-3424-2425"]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]},{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ryan D. Cassaday","raw_affiliation_strings":["UW/FHCRC, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UW/FHCRC, Seattle, WA","institution_ids":["https://openalex.org/I201448701","https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020858509","display_name":"Jonathan R. Fromm","orcid":"https://orcid.org/0000-0002-2287-5284","observed_orcids":["https://orcid.org/0000-0002-2287-5284"]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jonathan R. Fromm","raw_affiliation_strings":["Laboratory Medicine/Hematopathology, University of Washington, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Laboratory Medicine/Hematopathology, University of Washington, Seattle, WA","institution_ids":["https://openalex.org/I201448701"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5004025497","display_name":"Ajay K. Gopal","orcid":"https://orcid.org/0000-0003-3023-6834","observed_orcids":["https://orcid.org/0000-0003-3023-6834"]},"institutions":[{"id":"https://openalex.org/I201448701","display_name":"University of Washington","ror":"https://ror.org/00cvxb145","country_code":"US","type":"education","lineage":["https://openalex.org/I201448701"]},{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ajay K. Gopal","raw_affiliation_strings":["University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA","institution_ids":["https://openalex.org/I201448701","https://openalex.org/I4210089486"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5027819567","https://openalex.org/A5040951672","https://openalex.org/A5055972784","https://openalex.org/A5057524392"],"corresponding_institution_ids":["https://openalex.org/I201448701","https://openalex.org/I4210089486"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"132","issue":"Supplement 1","first_page":"1686","last_page":"1686"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10685","display_name":"Viral-associated cancers and disorders","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12212","display_name":"CNS Lymphoma Diagnosis and Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/diffuse-large-b-cell-lymphoma","display_name":"diffuse large B-cell lymphoma","score":0.9900000095367432},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.6520000100135803},{"id":"https://openalex.org/keywords/anti-pd-1-therapy","display_name":"anti-PD-1 therapy","score":0.8410000205039978},{"id":"https://openalex.org/keywords/immune-checkpoint-blockade","display_name":"immune checkpoint blockade","score":0.7919999957084656},{"id":"https://openalex.org/keywords/pd-l1-expression","display_name":"PD-L1 expression","score":0.7919999957084656},{"id":"https://openalex.org/keywords/anthracycline-based-chemotherapy","display_name":"anthracycline chemotherapy","score":0.7630000114440918},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.5360000133514404},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.6460000276565552},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9039999842643738},{"id":"https://openalex.org/keywords/relapsed-lymphoma","display_name":"relapsed lymphoma","score":0.6259999871253967},{"id":"https://openalex.org/keywords/transformed-lymphoma","display_name":"transformed lymphoma","score":0.9049999713897705}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7280033826828003},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.6354191303253174},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5964246392250061},{"id":"https://openalex.org/C2779429289","wikidata":"https://www.wikidata.org/wiki/Q408977","display_name":"Vincristine","level":4,"score":0.5556535124778748},{"id":"https://openalex.org/C2778559949","wikidata":"https://www.wikidata.org/wiki/Q2626074","display_name":"Diffuse large B-cell lymphoma","level":3,"score":0.5429248213768005},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.5351899862289429},{"id":"https://openalex.org/C2777058707","wikidata":"https://www.wikidata.org/wiki/Q123251","display_name":"Follicular lymphoma","level":3,"score":0.4934767484664917},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.47896721959114075},{"id":"https://openalex.org/C2778720950","wikidata":"https://www.wikidata.org/wiki/Q424972","display_name":"Prednisone","level":2,"score":0.4730084240436554},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.44473832845687866},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.422515332698822},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.34433770179748535},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3409509062767029},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.33256566524505615},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.18923836946487427},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.11149173974990845}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2018-99-119129","doi":"https://doi.org/10.1182/blood-2018-99-119129","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2018-99-119129","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2950348075","https://openalex.org/W3184587460","https://openalex.org/W3096835610","https://openalex.org/W4200188834","https://openalex.org/W4379282001","https://openalex.org/W4387745534","https://openalex.org/W4307338361","https://openalex.org/W4210378956","https://openalex.org/W4389220653","https://openalex.org/W2388873750"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"Rituximab":[2],"with":[3,49,59,84,103,114,156,184,374,380,410,580,592,631],"cyclophosphamide,":[4],"doxorubicin,":[5],"vincristine,":[6],"and":[7,54,109,218,238,252,274,333,377,389,416,418,470,484,496,550,571,598,607,641,656],"prednisone":[8],"(RCHOP)":[9],"remains":[10,276],"standard":[11,160],"therapy":[12,83,422],"for":[13,68,117,190,206,233,250,361,518,575],"previously":[14,40,104],"untreated":[15,105,634],"diffuse":[16],"large":[17],"B-cell":[18],"lymphoma":[19,108,113],"(DLBCL).":[20],"However,":[21],"a":[22,115,407,411,522],"substantial":[23],"proportion":[24],"of":[25,56,81,93,127,134,168,171,182,195,204,338,392,398,413,443,491,528,615,629],"patients":[26],"(pts)":[27],"will":[28,644],"relapse.":[29],"The":[30,349],"anti-PD-1":[31],"monoclonal":[32],"antibody":[33],"pembrolizumab":[34,143,581,630],"has":[35],"shown":[36],"modest":[37],"efficacy":[38],"in":[39,61,87,180,235,283,298,307,321,406,420,487,542,545,548,552,621,633,647],"treated":[41,261],"DLBCL.":[42],"We":[43,73],"postulated":[44],"that":[45],"the":[46,62,76,91,169,322,341,401,431,572],"first-line":[47],"setting,":[48],"relatively":[50],"intact":[51],"host":[52],"immunity":[53],"coexistence":[55],"malignant":[57],"cells":[58],"T-cells":[60],"microenvironment,":[63],"may":[64],"represent":[65],"an":[66],"opportunity":[67],"effective":[69],"immune":[70],"checkpoint":[71],"inhibition.":[72],"carried":[74],"out":[75],"first":[77,323],"known":[78],"prospective":[79],"trial":[80],"anti-PD1":[82],"anthracycline":[85,439,445],"chemotherapy":[86,632],"lymphoma,":[88],"to":[89,152,178,200,277,289,354,595],"evaluate":[90],"safety":[92],"this":[94],"combination.":[95],"Methods:":[96],"Pts":[97],"age":[98],"18":[99,291,465],"years":[100],"or":[101,132,198,617],"older":[102],"DLBCL,":[106,332],"transformed":[107],"grade":[110,174,292,370,383,386,393],"3B":[111],"follicular":[112],"plan":[116],"6-cycle,":[118],"curative-intent":[119],"RCHOP":[120,153,185,205,579,596],"were":[121,136,241,248,260],"eligible.":[122],"Steroids":[123],"within":[124],"7":[125,468,476],"days":[126],"treatment,":[128],"active":[129],"autoimmune":[130],"disease,":[131,502],"history":[133,412],"pneumonitis":[135,399],"excluded.":[137],"This":[138,396],"phase":[139],"I":[140],"study":[141,628],"combined":[142],"(200":[144],"mg":[145,583],"IV":[146],"q":[147,584],"3":[148,193,371,394,480,485,585],"weeks":[149,586],"x":[150,154,587],"6)":[151],"6,":[155],"supportive":[157],"care":[158],"per":[159],"practice.":[161],"A":[162,187],"30-pt":[163],"sample":[164],"size":[165],"permitted":[166],"estimation":[167],"rate":[170],"clinically":[172,294],"relevant":[173],"3-5":[175,293],"toxicity,":[176],"assumed":[177],"occur":[179],"40%":[181],"pts":[183,247,259,288,301,309,463,520],"alone.":[186],"stopping":[188,421],"rule":[189],"more":[191,618],"than":[192],"instances":[194],"non-relapse":[196],"death":[197,351],"inability":[199],"complete":[201],"6":[202,553,588],"cycles":[203,589],"any":[207],"reason":[208],"was":[209,225,400,441,455,540,619],"applied.":[210],"Secondary":[211],"endpoints":[212],"included":[213],"response":[214,245,458],"rates,":[215],"overall":[216],"(OS)":[217],"progression-free":[219],"survival":[220,642],"(PFS).":[221],"Baseline":[222,514],"PDL1":[223,539,561,611],"expression":[224,614],"analyzed":[226],"centrally":[227],"(Merck/Qualtek).":[228],"Peripheral":[229],"blood":[230],"flow":[231],"cytometry":[232],"changes":[234],"PD1,":[236],"PDL-1,":[237],"PDL-2":[239],"subsets":[240],"performed.":[242],"After":[243],"PET-based":[244],"assessment,":[246],"followed":[249],"relapse":[251],"survival.":[253],"Results:":[254],"Since":[255],"March":[256],"2016,":[257],"29":[258,287],"on":[262,272],"study;":[263],"28":[264],"have":[265],"finished":[266],"all":[267],"therapy.":[268],"One":[269,320],"is":[270,493,510,590],"currently":[271],"therapy,":[273],"1":[275,337,384,390,471,478,503,563],"be":[278,645],"enrolled.":[279],"Pt":[280],"characteristics":[281],"are":[282,609],"Table":[284],"1.":[285],"In":[286],"date,":[290],"significant":[295],"AE's":[296],"occurred":[297,306,352],"13":[299,494],"unique":[300],"(13/29,":[302],"45%).":[303],"16":[304],"SAE's":[305],"11":[308],"(11/29,":[310],"38%);":[311],"none":[312],"qualified":[313],"as":[314],"unanticipated":[315],"events.":[316],"Two":[317],"deaths":[318],"occurred:":[319,369],"accured":[324],"patient,":[325],"who":[326,433],"had":[327,481,558,566],"extensive":[328],"gastric":[329],"involvement":[330],"by":[331],"died":[334,434],"during":[335,435],"cycle":[336,424,436],"bleeding":[339],"from":[340],"responding":[342],"tumor":[343,525,560,569,612],"bed":[344],"despite":[345],"maximal":[346],"inpatient":[347],"intervention.":[348],"other":[350],"due":[353],"steroid-refractory":[355],"GVHD":[356],"after":[357,423,504,649],"haploidenticial":[358],"allogeneic":[359],"transplant":[360],"relapsed":[362],"disease.":[363,474],"Four":[364],"immune-related":[365,403],"adverse":[366],"events":[367],"(IRAE)":[368],"rash,":[372],"resolving":[373],"oral":[375],"steroids":[376],"not":[378],"recurring":[379],"further":[381,627],"pembrolizumab,":[382],"hyperthyroidism,":[385],"2":[387,497],"colitis,":[388],"episode":[391],"pneumonitis.":[395],"case":[397],"only":[402,599],"SAE,":[404],"occurring":[405],"78":[408],"yo":[409],"tobacco":[414],"use":[415],"COPD,":[417],"resulted":[419],"3.":[425],"Among":[426,475],"27":[427],"completing":[428],"treatment":[429],"(excluding":[430],"pt":[432,565],"1),":[437],"average":[438],"dose":[440,447,451,453,603],"95%":[442],"expected;":[444],"relative":[446],"intensity":[448],"(RDI:":[449],"delivered":[450],"intensity/standard":[452],"intensity)":[454],"94%.":[456],"PET":[457,505],"assessment":[459],"among":[460],"26":[461],"evaluable":[462],"showed":[464,521],"CR":[466,605],"(69%),":[467],"PR,":[469,477],"primary":[472,500],"refractory":[473],"relapsed,":[479],"negative":[482],"biopsies,":[483],"remain":[486],"remission.":[488],"Median":[489],"follow-up":[490],"survivors":[492],"months":[495],"relapses":[498],"(1":[499],"progressive":[501],"PR)":[506],"occurred.":[507],"One-year":[508],"PFS":[509,608],"87%":[511],"(Figure":[512],"1).":[513],"PDL-1":[515],"staining":[516,527],"available":[517],"19":[519],"median":[523],"%":[524],"cell":[526,613],"30%":[529],"(moderate":[530],"2+":[531],"plus":[532],"strong":[533],"3+":[534],"staining;":[535],"range,":[536],"0-100%).":[537],"Tumor":[538],"\u22645%":[541],"4,":[543,549],"10-29%":[544],"5,":[546],"30-49%":[547],"\u226550%":[551],"pts.":[554,623],"Both":[555],"EBV+":[556],"DLBCL":[557],"60%":[559],"expression.":[562],"relapsing":[564],"no":[567],"detectable":[568],"PDL1,":[570],"THRLBL":[573],"failed":[574],"technical":[576],"reasons.":[577],"Conclusions:":[578],"200":[582],"safe,":[591],"toxicity":[593],"similar":[594],"alone":[597],"4":[600],"IRAE's.":[601],"Anthracycline":[602],"intensity,":[604],"rate,":[606],"favorable.":[610],"10%":[616],"observed":[620],"15/19":[622],"These":[624],"data":[625,643],"support":[626],"lymphoid":[635],"malignancies.":[636],"Final":[637],"response/progression,":[638],"correlative":[639],"studies,":[640],"presented":[646],"December":[648],"final":[650],"accrual.":[651],"Disclosures":[652],"Smith:":[653],"Merck":[654],"Sharp":[655],"Dohme":[657],"Corp.:":[658],"Consultancy,":[659,776,799,810,825,837],"Research":[660,663,667,672,675,679,683,695,699,703,708,715,718,722,725,728,732,735,741,749,754,757,763,767,773,777,780,787,790,800,804,807,811,814,817,822,826,829,838,843],"Funding;":[661,664,668,673,676,680,696,700,704,719,723,726,733,736,742,750,755,758,764,768,778,781,788,791,801,808,812,815,818,823,827,830,839],"Pharmacyclics:":[662,756],"Portola":[665],"Pharmaceuticals:":[666,698,793],"Acerta":[669],"Pharma":[670],"BV:":[671],"Genentech:":[674,734,751],"Seattle":[677,782,835],"Genetics:":[678,772,783,836],"Incyte":[681,693],"Corporation:":[682,694],"Funding.":[684,709,716,729,774,805,844],"Lynch:Johnson":[685],"Graffe":[686],"Keay":[687],"Moniz":[688],"&":[689,713],"Wick":[690],"LLP:":[691],"Consultancy;":[692,738,747,752,760,794,797,820,832,834,841],"Takeda":[697],"T.G.":[701],"Therapeutics:":[702,721,766],"Rhizen":[705],"Pharmaceuticals":[706],"S.A.:":[707],"Till:Mustang":[710],"Bio:":[711],"Patents":[712],"Royalties,":[714],"Cowan:Sanofi:":[717],"Juno":[720],"Abbvie:":[724],"Janssen:":[727,809],"Shadman:Acerta":[730],"Pharma:":[731,803],"Verastem:":[737],"Gilead":[739],"Sciences:":[740],"Qilu":[743],"Puget":[744],"Sound":[745],"Biotherapeutics:":[746],"Celgene:":[748],"Beigene:":[753],"AbbVie:":[759],"Mustang":[761],"Biopharma:":[762],"TG":[765],"AstraZeneca:":[769],"Consultancy.":[770],"Shustov:Seattle":[771],"Cassaday:Amgen:":[775],"Incyte:":[779,819],"Other:":[784],"Spouse":[785],"Employment,":[786],"Merck:":[789,828],"Jazz":[792],"Adaptive":[795],"Biotechnologies:":[796],"Pfizer:":[798],"Kite":[802],"Gopal:Pfizer:":[806],"BMS:":[813],"Takeda:":[816],"Spectrum:":[821],"Gilead:":[824],"Aptevo:":[831],"Asana:":[833],"Brim:":[840],"Teva:":[842]},"counts_by_year":[{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2019-03-22T00:00:00"}